Niki BioSolutions, Inc. cash flow to debt ratio of -53.34% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Niki BioSolutions, Inc.'s free cash flow has decreased 54.37% from $-1.19M last year to $-1.84M, signaling decreasing performance

Niki BioSolutions, Inc.'s debt to equity ratio is 0.15, which means that the company's assets are healthy financed, signaling financial stability.

Niki BioSolutions, Inc.'s debt has decreased relative to shareholder equity from 0.16 last year to 0.15 today, signaling strengthened financials

Niki BioSolutions, Inc. has a net cash position, so leverage is healthy.

Niki BioSolutions, Inc.'s interest coverage ratio is -5.48, which means that the company struggles to meet interest obligations, signaling financial risk.

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc.'s short-term liabilities of $4.59M exceed its short-term assets of $3.59M, signaling financial risk

Niki BioSolutions, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Niki BioSolutions, Inc.'s return on equity of -5.94%, is lower than 15.00%, indicating bad performance

Niki BioSolutions, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Niki BioSolutions, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Niki BioSolutions, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Niki BioSolutions, Inc. has negative free cash flow, indicating cash burn

Niki BioSolutions, Inc.'s yearly earnings has increased 68.06% since last year from $-4.27M to $-1.36M, signaling increasing performance

Niki BioSolutions, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -2.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Niki BioSolutions, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Niki BioSolutions, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Niki BioSolutions, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Niki BioSolutions, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Niki BioSolutions, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Niki BioSolutions, Inc. has insufficient data to evaluate this check.

Niki BioSolutions, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Niki BioSolutions, Inc. has a price-to-book ratio of 0.03x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Niki BioSolutions, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue